Download MendeleyScaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines
De Vicente, J., Lemoine, R., Bartlett, M., Hermann, J.C., Hekmat-Nejad, M., Henningsen, R., Jin, S., Kuglstatter, A., Li, H., Lovey, A.J., Menke, J., Niu, L., Patel, V., Petersen, A., Setti, L., Shao, A., Tivitmahaisoon, P., Vu, M.D., Soth, M.(2014) Bioorg Med Chem Lett 24: 4969-4975
- PubMed: 25262541
- DOI: https://doi.org/10.1016/j.bmcl.2014.09.031
- Primary Citation of Related Structures:
4QT1 - PubMed Abstract:
The discovery of a novel series of pyrrolopyrazines as JAK inhibitors with comparable enzyme and cellular activity to tofacitinib is described. The series was identified using a scaffold hopping approach aided by structure based drug design using principles of intramolecular hydrogen bonding for conformational restriction and targeting specific pockets for modulating kinase activity.
Organizational Affiliation:
Small Molecule Research, Pharma Research & Early Development, pRED, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, United States. Electronic address: javier.devicente@novartis.com.
